Ashray Gunjur. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » Antineoplastic Combined Chemotherapy Protocols/adverse effectsAntineoplastic Combined Chemotherapy Protocols/therapeutic useCarcinoma, Renal Cell/drug therapyCarcinoma, Renal Cell/mortalityCarcinoma, Renal Cell/pathologyClinical Trials, Phase III as TopicDisease ProgressionHumansIpilimumab/administration & dosageIpilimumab/adverse effectsKidney Neoplasms/drug therapyKidney Neoplasms/mortalityKidney Neoplasms/pathologyNivolumab/administration & dosageNivolumab/adverse effectsProgression-Free SurvivalRandomized Controlled Trials as TopicTime Factors
Substances: See more » IpilimumabNivolumab
Year: 2018 PMID: 29606588 DOI: 10.1016/S1470-2045(18)30257-2
Source DB: PubMed Journal: Lancet Oncol ISSN: 1470-2045 Impact factor: 41.316